Back to results
US 2020/0345838 A1Published application
A Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein
AssigneesUniversity of Washington, Abacus Bioscience, Inc.
InventorsEdward A. CLARK, Che-Leung LAW, Deborah FULLER, Michael GALE
Life of this patent
Estimating the term…
Abstract
Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.
Claims22
A composition, comprising:
- (a) CD180 binding ligand;
- and
- (b) a Hepatitis B antigen selected from the group consisting of a Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, M-HBsAg, S-HBsAg, or antigenic fragments or mutants thereof, wherein the Hepatitis B antigen is attached to the CD180 binding ligand.
-18. (canceled)
-28. (canceled)
Dependencies are inferred from the claim text.